APA (7th ed.) Citation

N, S., E, G., G, R., G, B., V, S., G, F., . . . F, R. (2022). Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program. Current oncology (Toronto, Ont.), 29(9), 6635. https://doi.org/10.3390/curroncol29090521

Chicago Style (17th ed.) Citation

N, Staropoli, et al. "Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program." Current Oncology (Toronto, Ont.) 29, no. 9 (2022): 6635. https://doi.org/10.3390/curroncol29090521.

MLA (9th ed.) Citation

N, Staropoli, et al. "Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program." Current Oncology (Toronto, Ont.), vol. 29, no. 9, 2022, p. 6635, https://doi.org/10.3390/curroncol29090521.